

Fundamentals




OF SPONSORED PROJECTS AT CSU

4th Week of February, 2024

“Award Types and Setup”

Differences between award mechanisms and how we utilize them.



Important Links

- [OSP Staff Directory](#)
- [Non-Financial Agreements](#)
- [Award Receipt & Negotiation](#)
- [Account Setup](#)
- [Kuali Research Resources](#)
- [Research Integrity, Safety, and Compliance](#)

Account Types

- 53 =
- 88/89 =
- 21 =
- 22 =
- 64 =



YOUTUBE TUESDAY

UNFUNDED AGREEMENTS

FT. KARIM HUSSEIN, UC SAN FRANCISCO; KATARINA TANG, UC SAN DIEGO; &



NCURA
Supporting Research...together™

JEFFREY WARNER, UNIVERSITY OF CENTRAL FLORIDA



Check out this short video about Unfunded Agreements

- MTA: _____
- NDA/CDA: _____
- DUA: _____
- MOU: _____



FUNDAMENTALS OF SPONSORED PROJECTS AT CSU

What can I do in my role to support speedy setup?



Key Aspects to a Notice of Award

Pop Quiz

Q1: Who does the DRA or PI contact with questions about the award?

1. OSP SRA/RA
2. Sponsor Technical Officer
3. Program Officer



Q2: Who can sign an award obligating the University?

1. Program Office
2. Authorized Organizational Representative
3. Principal Investigator
4. Any University Employee

Q3: Which award mechanism is used when substantial involvement is anticipated between the sponsor and recipient?


1. Cooperative Agreement
2. Grant
3. Fixed Price Contract

Other Notes





Answer Key.

- A1:** OSP SRA/RA
- A2:** Authorized Organizational Representatives (AOR) can sign awards to obligate the Institution.
- A3:** Cooperative Agreement



Homework

Complete an online Module in MyLearning



Office Hours

Do you have questions about topics covered in these sessions? We have you covered.

Join us on **Fridays in February** for Office Hours:

- Friday, February 9th; 10:00 - 11:00 am
- Friday, February 16th; 10:00 - 11:00 am
- Friday, February 23rd; 10:00 - 11:00 am



Click here to join the Teams Meeting!

If you are unable to join us and have questions, comments, or concerns, please contact the OSP Training Team:

- OSP_Info@colostate.edu
- Shannon Irely, shannon.irely@colostate.edu
- Kathryn O'Hayre, kathryn.ohayre@colostate.edu



Survey.



Please take a moment to complete the anonymous survey for this session and let us and the presenters know what we can improve or if there is anything more you need. We value your feedback and use the information to create future training.

Click here for the survey.





<p>Recipient Information</p> <p>1. Recipient Name COLORADO STATE UNIVERSITY 601 S HOWES ST FORT COLLINS, CO 80521</p> <p>2. Congressional District of Recipient 02</p> <p>3. Payment System Identifier (ID) 1846000545A1</p> <p>4. Employer Identification Number (EIN) 846000545</p> <p>5. Data Universal Numbering System (DUNS) 785979618</p> <p>6. Recipient's Unique Entity Identifier LT9CXX8L19G1</p> <p>7. Project Director or Principal Investigator Cam DeRam, PHD cam.deram@colostate.edu 303-492-6533</p> <p>8. Authorized Official Maria Lockhart</p>	<p>Federal Award Information</p> <p>11. Award Number 1R35GM123456-01</p> <p>12. Unique Federal Award Identification Number (FAIN) R35GM123456</p> <p>13. Statutory Authority 42 USC 241 42 CFR 52</p> <p>14. Federal Award Project Title Ground Breaking Work in Photoredox Catalysis</p> <p>15. Assistance Listing Number 93.859</p> <p>16. Assistance Listing Program Title Biomedical Research and Research Training</p> <p>17. Award Action Type New Competing</p> <p>18. Is the Award R&D? Yes</p>																								
<p>Federal Agency Information</p> <p>9. Awarding Agency Contact Information Julie A Chang NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES Julie.Chang@nih.gov (301) 555-0097</p> <p>10. Program Official Contact Information Jiong Yang NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES jiong.yang@nih.gov 301-555-1829</p>	<p>Summary Federal Award Financial Information</p> <table border="1"> <tr> <td colspan="2">19. Budget Period Start Date 02/01/2022 – End Date 01/31/2023</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$473,709</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$341,969</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$131,740</td> </tr> <tr> <td>21. Authorized Carryover</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>22. Offset</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$473,709</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$473,709</td> </tr> <tr> <td colspan="2">-----</td> </tr> <tr> <td colspan="2">26. Project Period Start Date 02/01/2022 – End Date 01/31/2027</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$473,709</td> </tr> </table> <p>28. Authorized Treatment of Program Income Additional Costs</p> <p>29. Grants Management Officer - Signature Lisa Moeller</p>	19. Budget Period Start Date 02/01/2022 – End Date 01/31/2023		20. Total Amount of Federal Funds Obligated by this Action	\$473,709	20 a. Direct Cost Amount	\$341,969	20 b. Indirect Cost Amount	\$131,740	21. Authorized Carryover	\$0	22. Offset	\$0	23. Total Amount of Federal Funds Obligated this budget period	\$473,709	24. Total Approved Cost Sharing or Matching, where applicable	\$0	25. Total Federal and Non-Federal Approved this Budget Period	\$473,709	-----		26. Project Period Start Date 02/01/2022 – End Date 01/31/2027		27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$473,709
19. Budget Period Start Date 02/01/2022 – End Date 01/31/2023																									
20. Total Amount of Federal Funds Obligated by this Action	\$473,709																								
20 a. Direct Cost Amount	\$341,969																								
20 b. Indirect Cost Amount	\$131,740																								
21. Authorized Carryover	\$0																								
22. Offset	\$0																								
23. Total Amount of Federal Funds Obligated this budget period	\$473,709																								
24. Total Approved Cost Sharing or Matching, where applicable	\$0																								
25. Total Federal and Non-Federal Approved this Budget Period	\$473,709																								

26. Project Period Start Date 02/01/2022 – End Date 01/31/2027																									
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$473,709																								
<p>30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.</p>																									



SECTION I – AWARD DATA – 1R35GM123456-01

Principal Investigator(s):

Cam DeRam, PHD

Award e-mailed to: SP@research.colostate.EDU

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$473,709 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to COLORADO STATE UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number R35GM123456. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Lisa Moeller
Grants Management Officer
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Federal Direct Costs	\$341,969
Federal F&A Costs	\$131,740
Approved Budget	\$473,709
Total Amount of Federal Funds Authorized (Federal Share)	\$473,709
TOTAL FEDERAL AWARD AMOUNT	\$473,709
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$473,709

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$473,709	\$473,709
2	\$374,672	\$374,672
3	\$374,246	\$374,246
4	\$373,785	\$373,785
5	\$373,288	\$373,288

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1846000545A1
Document Number: RGM123456A
PMS Account Type: P (Subaccount)
Fiscal Year: 2022

IC	CAN	2022	2023	2024	2025	2026
GM	8472185	\$473,709	\$374,672	\$374,246	\$373,785	\$373,288

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: P266JY / **OC:** 41021 / **Released:** Moeller, Lisa 12/22/2021
Award Processed: 01/05/2022 12:07:53 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R35GM123456-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 1R35GM123456-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R35GM144356. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – GM SPECIFIC AWARD CONDITIONS – 1R35GM123456-01

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

1. This award is subject to the conditions set forth in RFA-PAR19-367, "Maximizing Investigators' Research Award (R35)," which are hereby incorporated by reference as special terms and conditions of this award. Copies of this Funding Opportunity Announcement can be found at the following link: <http://grants.nih.gov/grants/guide/index.html>.

2. The Principal Investigator is required to devote at least 51% of his/her research effort on this R35 (MIRA).

3. The Principal Investigator of this MIRA grant is restricted from receiving other sources of NIGMS funding other than the exceptions referenced in the MIRA funding opportunity announcement (FOA).

4. None of the funds in this award shall be used to pay the salary of an individual at a rate in excess of the current salary cap. Therefore, this award and/or future years are adjusted accordingly, if applicable.

Current salary cap levels can be found at the following URL:

http://grants.nih.gov/grants/policy/salcap_summary.htm

5. As appropriate, the awardee is required to follow the sharing plan(s) for unique research resources (i.e. Data, Model Organism, Genomic Data, or other) associated with this project and may not implement any changes to the plan(s) without the written prior approval of the National Institute of General Medical Sciences.

SECTION V - NIGMS CONTACTS

The NIGMS WWW home page is at <http://www.nigms.nih.gov>

SPREADSHEET SUMMARY

AWARD NUMBER: 1R35GM123456-01

INSTITUTION: COLORADO STATE UNIVERSITY

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	52%	52%	52%	52%	52%
F&A Cost Base 1	\$253,347	\$239,753	\$238,935	\$238,049	\$237,093
F&A Costs 1	\$131,740	\$124,672	\$124,246	\$123,785	\$123,288